Novo cancels haemophilia drug Phase III trial
Haemophilia is a mostly inherited genetic disorder that impairs the body’s ability to make blood clots.
Read More
Tag: concizumab
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
